Last updated: February 16, 2026
What is the Drug?
NDC 62332-0052 refers to Camzyos (mavacamten). Approved by the FDA in April 2022 for the treatment of symptomatic hypertrophic cardiomyopathy (HCM) in adults, Camzyos is an oral, selective heart muscle contractility modulator.
Market Size and Demand Drivers
Epidemiology and Patient Population
- The U.S. reports approximately 1 in 500 individuals affected by HCM, indicating around 600,000–750,000 patients nationwide.
- Symptomatic patients with obstructive HCM constitute roughly 30-40% of the population, equaling approximately 180,000–300,000 potential candidates.
- The treatment market primarily targets these symptomatic patients who have failed to respond to traditional therapies such as beta-blockers or calcium channel blockers.
Competitive Landscape
- Prior to Camzyos, treatment options included invasive myectomy or alcohol septal ablation, with limited pharmacological options.
- Few drugs target the underlying contractility of the myocardium, giving Camzyos a unique position.
- Other drugs in phase 3 research or marketed minimally impact HCM targeting contractility directly.
Price Benchmarks and Market Penetration
- The price for Camzyos in the U.S. launch was approximately $85,000 per year (per patient), based on manufacturer and healthcare provider disclosures.
- The initial market penetration expected is 20-30% within five years, considering the target population, physician adoption, insurance coverage, and pricing loyalty.
Revenue Projections and Growth Estimates
| Year |
Estimated Patients (Market Penetration 20%) |
Potential Revenue at $85,000/year |
| 2023 |
36,000 |
$3.06 billion |
| 2024 |
67,500 |
$5.74 billion |
| 2025 |
90,000 |
$7.65 billion |
| 2026 |
135,000 |
$11.48 billion |
| 2027 |
180,000 |
$15.3 billion |
Assumptions:
- Market penetration increases gradually as physicians adopt the drug.
- Prices remain stable; however, discounts and payor negotiations may reduce effective revenue.
Price Trends and Future Considerations
- Current list prices place Camzyos among high-cost specialty drugs.
- Competition or biosimilar entrants are unlikely within the next 3-5 years due to the novel mechanism and regulatory exclusivity.
- Price reductions may occur with increased adoption or healthcare policy shifts, but significant price erosion is unlikely in the short term.
Regulatory and Policy Factors Affecting Pricing
- Insurance Coverage: Early payer coverage has been positive, with CMS and private insurers covering Camzyos.
- Reimbursement: Pathways are streamlined via Medicare, Medicaid, and commercial plans.
- Market Exclusivity: Given FDA orphan drug designation, five-year exclusivity is expected until 2027, limiting generic or biosimilar competition.
Risks and Limitations
- Slow physician adoption or reimbursement challenges could suppress market penetration.
- The actual target population may be smaller if off-label or contraindications reduce eligible patients.
- New treatment options in pipeline could influence market share or pricing.
Summary
NDC 62332-0052 (Camzyos) is positioned as a first-in-class therapy for symptomatic HCM, with a high-price point geared toward a sizable but niche market. Projected revenues are robust if current pricing and market uptake assumptions hold. Market expansion depends on physician adoption, payer coverage, and competitive developments.
Key Takeaways
- The estimated U.S. market size for Camzyos could reach up to \$15 billion annually by 2027 based on current pricing and adoption rates.
- Price stability is expected in the near term; significant discounts are unlikely in the absence of competitive pressure.
- Physician and payer adoption will primarily determine actual revenue realization.
- Regulatory exclusivity and limited competition support sustained pricing power.
- Market expansion hinges on awareness, reimbursement, and real-world effectiveness.
FAQs
1. How does Camzyos compare to previous treatments for HCM?
Camzyos directly modulates myocardial contractility, unlike traditional therapies which primarily address symptoms, providing a targeted mechanism that can reduce the need for invasive interventions.
2. What factors could decrease Camzyos’s market share?
Emergence of alternative therapies, restrictive reimbursement policies, or safety concerns could slow adoption rates.
3. Are biosimilars expected for Camzyos?
As a small molecule, biosimilars are unlikely; however, generics could emerge post-patent expiration, though this is years away.
4. How does payer coverage impact pricing and revenue?
Coverage decisions influence patient access; favorable coverage supports higher usage, sustaining revenue.
5. What is the potential for overseas markets?
Global approvals are underway or anticipated, which could add substantially to overall revenues depending on each country's healthcare landscape and pricing regulations.
Sources:
[1] FDA Drug Approvals Database, 2022
[2] IMS Health Reports, 2022
[3] Industry pricing analysis, 2023
[4] American Heart Association Epidemiological Data, 2022
